Sosin Michael, De La Cruz Carla, Mundinger Gerhard S, Saadat Sean Y, Nam Arthur J, Manson Paul N, Christy Michael R, Bojovic Branko, Rodriguez Eduardo D
Baltimore, Md.; New York, N.Y.; and Washington, D.C. From the Division of Plastic, Reconstructive and Maxillofacial Surgery, R Adams Cowley Shock Trauma Center, University of Maryland Medical Center; the Department of Plastic and Reconstructive Surgery, Johns Hopkins Hospital; the Department of Plastic Surgery, New York University Langone Medical Center; and the George Washington University School of Medicine and Health Sciences.
Plast Reconstr Surg. 2016 Jan;137(1):231-238. doi: 10.1097/PRS.0000000000001907.
Traumatic optic neuropathy is characterized by sudden loss of vision following facial trauma leading to variable visual deficits. The purpose of this study was to evaluate recent institutional trends in the treatment of traumatic optic neuropathy, evaluate the outcomes of different treatment strategies, and identify factors associated with improved vision.
Institutional review board approval was obtained to retrospectively review patients diagnosed with traumatic optic neuropathy at a high-volume trauma center from 2004 to 2012. Pretreatment and posttreatment visual acuity was compared using quantitative analysis of standard ophthalmologic conversion.
A total of 109 patients met inclusion criteria (74.3 percent male patients), with a mean age of 38.0 ± 17.5 years (range, 8 to 82 years). Management of traumatic optic neuropathy involved intravenous corticosteroids alone in 8.3 percent of patients (n = 9), 56.9 percent (n = 62) underwent observation, 28.4 percent (n = 31) had surgical intervention, and 6.4 percent (n = 7) underwent surgery and corticosteroid administration. Only 19.3 percent of patients returned for follow-up. Vision improved in 47.6 percent of patients, with a mean follow-up of 12.9 weeks. Patients younger than 50 years had a trend toward higher rates of visual improvement, 60 percent versus 16.7 percent (p = 0.15).
The majority of traumatic optic neuropathy patients are unlikely to return for a follow-up examination. Optic nerve decompression has fallen out of favor in the authors' institution, and observation is the most common management strategy. Outcomes following corticosteroid administration and observation are comparable.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
创伤性视神经病变的特征是面部创伤后突然视力丧失,导致不同程度的视力缺陷。本研究的目的是评估创伤性视神经病变治疗的近期机构趋势,评估不同治疗策略的结果,并确定与视力改善相关的因素。
获得机构审查委员会批准,对2004年至2012年在一家大型创伤中心诊断为创伤性视神经病变的患者进行回顾性研究。使用标准眼科转换的定量分析比较治疗前和治疗后的视力。
共有109例患者符合纳入标准(男性患者占74.3%),平均年龄为38.0±17.5岁(范围为8至82岁)。8.3%的患者(n = 9)仅接受静脉注射皮质类固醇治疗,56.9%(n = 62)接受观察,28.4%(n = 31)接受手术干预,6.4%(n = 7)接受手术并使用皮质类固醇。只有19.3%的患者返回进行随访。47.6%的患者视力得到改善,平均随访12.9周。50岁以下的患者视力改善率有更高的趋势,分别为60%和16.7%(p = 0.15)。
大多数创伤性视神经病变患者不太可能返回进行随访检查。在作者所在机构,视神经减压术已不受青睐,观察是最常见的管理策略。皮质类固醇治疗和观察后的结果相当。
临床问题/证据水平:治疗性,IV级。